{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:36:09Z","timestamp":1789673769314,"version":"4.0.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["GIPD Project Code:96825"],"award-info":[{"award-number":["GIPD Project Code:96825"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["GIPD Project Code:96830"],"award-info":[{"award-number":["GIPD Project Code:96830"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["GIPD Project Code:96830"],"award-info":[{"award-number":["GIPD Project Code:96830"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-96161-w","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T10:48:56Z","timestamp":1744627736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Integrated renin angiotensin system dysregulation and immune profiles predict COVID-19 disease severity in a South African cohort"],"prefix":"10.1038","volume":"15","author":[{"given":"Talitha","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonwabile","family":"Dzanibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cascia","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phelelani Thokozani","family":"Mpangase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tafadzwa","family":"Chimbetete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Pedretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylva","family":"Schwager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive M.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Sturrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonny","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"96161_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280e278. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052 (2020).","journal-title":"Cell"},{"key":"96161_CR2","doi-asserted-by":"publisher","first-page":"109886","DOI":"10.1016\/j.mehy.2020.109886","volume":"143","author":"LAD Nicolau","year":"2020","unstructured":"Nicolau, L. A. D., Magalhaes, P. J. C. & Vale, M. L. What would S\u00e9rgio Ferreira say to your physician in this war against COVID-19: how about the Kallikrein\/kinin system? Med. Hypotheses. 143, 109886. https:\/\/doi.org\/10.1016\/j.mehy.2020.109886 (2020).","journal-title":"Med. Hypotheses"},{"key":"96161_CR3","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1161\/hypertensionaha.120.15841","volume":"76","author":"U Kintscher","year":"2020","unstructured":"Kintscher, U. et al. Plasma angiotensin peptide profiling and ACE (angiotensin-converting enzyme)-2 activity in COVID-19 patients treated with Pharmacological blockers of the renin-angiotensin system. Hypertension 76, e34\u2013e36. https:\/\/doi.org\/10.1161\/hypertensionaha.120.15841 (2020).","journal-title":"Hypertension"},{"key":"96161_CR4","doi-asserted-by":"publisher","first-page":"20117","DOI":"10.1038\/s41598-022-24628-1","volume":"12","author":"R Reindl-Schwaighofer","year":"2022","unstructured":"Reindl-Schwaighofer, R. et al. The systemic renin-angiotensin system in COVID-19. Sci. Rep. 12, 20117. https:\/\/doi.org\/10.1038\/s41598-022-24628-1 (2022).","journal-title":"Sci. Rep."},{"key":"96161_CR5","doi-asserted-by":"publisher","first-page":"175346662211225","DOI":"10.1177\/17534666221122544","volume":"16","author":"LM Amezcua-Guerra","year":"2022","unstructured":"Amezcua-Guerra, L. M. et al. The prognostic importance of the angiotensin II\/angiotensin-(1\u20137) ratio in patients with SARS-CoV-2 infection. Ther. Adv. Respir Dis. 16, 17534666221122544. https:\/\/doi.org\/10.1177\/17534666221122544 (2022).","journal-title":"Ther. Adv. Respir Dis."},{"key":"96161_CR6","doi-asserted-by":"publisher","first-page":"e59177","DOI":"10.7554\/eLife.59177","volume":"9","author":"MR Garvin","year":"2020","unstructured":"Garvin, M. R. et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated Bradykinin storm. Elife 9, e59177. https:\/\/doi.org\/10.7554\/eLife.59177 (2020).","journal-title":"Elife"},{"key":"96161_CR7","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/s41556-021-00796-6","volume":"23","author":"S Wang","year":"2021","unstructured":"Wang, S. et al. A single-cell transcriptomic landscape of the lungs of patients with COVID-19. Nat. Cell. Biol. 23, 1314\u20131328. https:\/\/doi.org\/10.1038\/s41556-021-00796-6 (2021).","journal-title":"Nat. Cell. Biol."},{"key":"96161_CR8","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.3390\/cells10102755","volume":"10","author":"F Pucci","year":"2021","unstructured":"Pucci, F., Annoni, F., Dos Santos, R. A. S., Taccone, F. S. & Rooman, M. Quantifying renin-angiotensin-system alterations in COVID-19. Cells 10, 2755. https:\/\/doi.org\/10.3390\/cells10102755 (2021).","journal-title":"Cells"},{"key":"96161_CR9","doi-asserted-by":"publisher","first-page":"00567","DOI":"10.1183\/23120541.00567-2023","volume":"10","author":"M Bauer","year":"2024","unstructured":"Bauer, M. et al. Phase I dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an inhaled Recombinant human ACE2. ERJ Open. Res. 10, 00567\u201302023. https:\/\/doi.org\/10.1183\/23120541.00567-2023 (2024).","journal-title":"ERJ Open. Res."},{"key":"96161_CR10","doi-asserted-by":"publisher","first-page":"e213594","DOI":"10.1001\/jamanetworkopen.2021.3594","volume":"4","author":"R Baral","year":"2021","unstructured":"Baral, R. et al. Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: A systematic review and meta-analysis. JAMA Netw. Open. 4, e213594. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.3594 (2021).","journal-title":"JAMA Netw. Open."},{"key":"96161_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/ehjcvp\/pvad067","volume":"10","author":"MMY Lee","year":"2024","unstructured":"Lee, M. M. Y. et al. Effects of renin-angiotensin system blockers on outcomes from COVID-19: A systematic review and meta-analysis of randomized controlled trials. Eur. Heart J. Cardiovasc. Pharmacother. 10, 68\u201380. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad067 (2024).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother"},{"key":"96161_CR12","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1038\/s41467-021-25191-5","volume":"12","author":"M Perreau","year":"2021","unstructured":"Perreau, M. et al. The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients. Nat. Commun. 12, 4888. https:\/\/doi.org\/10.1038\/s41467-021-25191-5 (2021).","journal-title":"Nat. Commun."},{"key":"96161_CR13","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","volume":"11","author":"B Diao","year":"2020","unstructured":"Diao, B. et al. Reduction and functional exhaustion of t cells in patients with coronavirus disease 2019 (COVID-19). Front. Immunol. 11, 827. https:\/\/doi.org\/10.3389\/fimmu.2020.00827 (2020).","journal-title":"Front. Immunol."},{"key":"96161_CR14","doi-asserted-by":"publisher","first-page":"107388","DOI":"10.1016\/j.jbc.2024.107388","volume":"300","author":"KE Bernstein","year":"2024","unstructured":"Bernstein, K. E. et al. Classical and nonclassical effects of angiotensin-converting enzyme: how increased ACE enhances myeloid immune function. J. Biol. Chem. 300, 107388. https:\/\/doi.org\/10.1016\/j.jbc.2024.107388 (2024).","journal-title":"J. Biol. Chem."},{"key":"96161_CR15","doi-asserted-by":"publisher","first-page":"eaan5616","DOI":"10.1126\/scitranslmed.aan5616","volume":"9","author":"M Pinter","year":"2017","unstructured":"Pinter, M. & Jain, R. K. Targeting the renin-angiotensin system to improve cancer treatment: implications for immunotherapy. Sci. Transl Med. 9, eaan5616. https:\/\/doi.org\/10.1126\/scitranslmed.aan5616 (2017).","journal-title":"Sci. Transl Med."},{"key":"96161_CR16","doi-asserted-by":"publisher","first-page":"101414","DOI":"10.1016\/j.eclinm.2022.101414","volume":"48","author":"CM Upton","year":"2022","unstructured":"Upton, C. M. et al. Safety and efficacy of Bcg re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial. EClinicalMedicine 48, 101414. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101414 (2022).","journal-title":"EClinicalMedicine"},{"key":"96161_CR17","unstructured":"National Institute of Communicable Diseases. Data from sequencing and variant typing of laboratory confirmed cases of COVID-19 patients enrolled in syndromic surveillance for respiratory illness in South Africa, March 2020\u2013September 2021. Commun. Dis. Commun. 20, 3\u20134. https:\/\/www.nicd.ac.za\/wp-content\/uploads\/2021\/09\/Data-from-sequencing-and-variant-typing-of-laboratoryconfirmed-cases-of-COVID-19-patients-enrolled-in-syndromic-surveillance-for-respiratory-illness-in-South-Africa-March-2020-September-2021.pdf (2021)."},{"key":"96161_CR18","doi-asserted-by":"crossref","unstructured":"World Health Organization. Clinical Management of COVID-19: Interim Guidance, 27 May 2020 (World Health Organization, 2020). https:\/\/iris.who.int\/handle\/10665\/332196","DOI":"10.15557\/PiMR.2020.0004"},{"key":"96161_CR19","doi-asserted-by":"publisher","first-page":"973","DOI":"10.7196\/samj.2020.v110i10.15157","volume":"110","author":"M Mendelson","year":"2020","unstructured":"Mendelson, M. et al. Clinical management of COVID-19: experiences of the COVID-19 epidemic from Groote Schuur hospital, cape town, South Africa. S Afr. Med. J. 110, 973\u2013981. https:\/\/doi.org\/10.7196\/samj.2020.v110i10.15157 (2020).","journal-title":"S Afr. Med. J."},{"key":"96161_CR20","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3390\/diagnostics11061091","volume":"11","author":"AA Rabaan","year":"2021","unstructured":"Rabaan, A. A. et al. Viral dynamics and real-time RT-PCR CT values correlation with disease severity in COVID-19. Diagnostics (Basel). 11, 1091. https:\/\/doi.org\/10.3390\/diagnostics11061091 (2021).","journal-title":"Diagnostics (Basel)"},{"key":"96161_CR21","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","volume":"7","author":"BJ Willett","year":"2022","unstructured":"Willett, B. J. et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat. Microbiol. 7, 1161\u20131179. https:\/\/doi.org\/10.1038\/s41564-022-01143-7 (2022).","journal-title":"Nat. Microbiol."},{"key":"96161_CR22","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/bioinformatics\/bty710","volume":"35","author":"L Shi","year":"2019","unstructured":"Shi, L., Westerhuis, J. A., Ros\u00e9n, J., Landberg, R. & Brunius, C. Variable selection and validation in multivariate modelling. Bioinformatics 35, 972\u2013980. https:\/\/doi.org\/10.1093\/bioinformatics\/bty710 (2019).","journal-title":"Bioinformatics"},{"key":"96161_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijid.2021.11.028","volume":"115","author":"M Fagyas","year":"2022","unstructured":"Fagyas, M. et al. Circulating ACE2 activity predicts mortality and disease severity in hospitalized COVID-19 patients. Int. J. Infect. Dis. 115, 8\u201316. https:\/\/doi.org\/10.1016\/j.ijid.2021.11.028 (2022).","journal-title":"Int. J. Infect. Dis."},{"key":"96161_CR24","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/HJH.0000000000003054","volume":"40","author":"S Akin","year":"2022","unstructured":"Akin, S. et al. A low aldosterone\/renin ratio and high soluble ACE2 associate with COVID-19 severity. J. Hypertens. 40, 606\u2013614. https:\/\/doi.org\/10.1097\/HJH.0000000000003054 (2022).","journal-title":"J. Hypertens."},{"key":"96161_CR25","doi-asserted-by":"publisher","first-page":"625732","DOI":"10.3389\/fimmu.2021.625732","volume":"12","author":"IO Osman","year":"2021","unstructured":"Osman, I. O. et al. Expression of ACE2, soluble ACE2, angiotensin I, angiotensin II and angiotensin-(1\u20137) is modulated in COVID-19 patients. Front. Immunol. 12, 625732. https:\/\/doi.org\/10.3389\/fimmu.2021.625732 (2021).","journal-title":"Front. Immunol."},{"key":"96161_CR26","doi-asserted-by":"publisher","first-page":"bvac144","DOI":"10.1210\/jendso\/bvac144","volume":"6","author":"NI Parikh","year":"2022","unstructured":"Parikh, N. I. et al. Hospitalized patients with COVID-19 have higher plasma aldosterone-renin ratio and lower ACE activity than controls. J. Endocr. Soc. 6, bvac144. https:\/\/doi.org\/10.1210\/jendso\/bvac144 (2022).","journal-title":"J. Endocr. Soc."},{"key":"96161_CR27","doi-asserted-by":"publisher","first-page":"5908","DOI":"10.1002\/jmv.27144","volume":"93","author":"A Lundstr\u00f6m","year":"2021","unstructured":"Lundstr\u00f6m, A. et al. Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers. J. Med. Virol. 93, 5908\u20135916. https:\/\/doi.org\/10.1002\/jmv.27144 (2021).","journal-title":"J. Med. Virol."},{"key":"96161_CR28","doi-asserted-by":"publisher","first-page":"L84","DOI":"10.1152\/ajplung.00071.2009","volume":"297","author":"HP Jia","year":"2009","unstructured":"Jia, H. P. et al. Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. Am. J. Physiol. Lung Cell. Mol. Physiol. 297, L84\u201396. https:\/\/doi.org\/10.1152\/ajplung.00071.2009 (2009).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"96161_CR29","doi-asserted-by":"publisher","first-page":"7809","DOI":"10.1073\/pnas.0711241105","volume":"105","author":"S Haga","year":"2008","unstructured":"Haga, S. et al. Modulation of TNF-alpha-converting enzyme by the Spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. Proc. Natl. Acad. Sci. U S A. 105, 7809\u20137814. https:\/\/doi.org\/10.1073\/pnas.0711241105 (2008).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"96161_CR30","doi-asserted-by":"publisher","first-page":"30113","DOI":"10.1074\/jbc.M505111200","volume":"280","author":"DW Lambert","year":"2005","unstructured":"Lambert, D. W. et al. Tumor necrosis factor-convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J. Biol. Chem. 280, 30113\u201330119. https:\/\/doi.org\/10.1074\/jbc.M505111200 (2005).","journal-title":"J. Biol. Chem."},{"key":"96161_CR31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.4049\/jimmunol.0804253","volume":"183","author":"EM Hanson","year":"2009","unstructured":"Hanson, E. M., Clements, V. K., Sinha, P., Ilkovitch, D. & Ostrand-Rosenberg, S. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4\u2009+\u2009and CD8\u2009+\u2009T cells. J. Immunol. 183, 937\u2013944. https:\/\/doi.org\/10.4049\/jimmunol.0804253 (2009).","journal-title":"J. Immunol."},{"key":"96161_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.yjmcc.2013.11.017","volume":"66","author":"VB Patel","year":"2014","unstructured":"Patel, V. B., Clarke, N. & Wang, Z. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE\/ADAM-17: A positive feedback mechanism in the RAS. J. Mol. Cell. Cardiol. 66, 167\u2013176. https:\/\/doi.org\/10.1016\/j.yjmcc.2013.11.017 (2014).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"96161_CR33","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1111\/jcmm.16714","volume":"25","author":"D Ma","year":"2021","unstructured":"Ma, D. et al. Single-cell RNA sequencing identify SDCBP in ACE2-positive bronchial epithelial cells negatively correlates with COVID-19 severity. J. Cell. Mol. Med. 25, 7001\u20137012. https:\/\/doi.org\/10.1111\/jcmm.16714 (2021).","journal-title":"J. Cell. Mol. Med."},{"key":"96161_CR34","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1186\/s12879-020-05619-x","volume":"20","author":"Z Zhu","year":"2020","unstructured":"Zhu, Z. et al. The potential role of serum angiotensin-converting enzyme in coronavirus disease 2019. BMC Infect. Dis. 20, 883. https:\/\/doi.org\/10.1186\/s12879-020-05619-x (2020).","journal-title":"BMC Infect. Dis."},{"key":"96161_CR35","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1164\/rccm.201912-2504LE","volume":"202","author":"K Krenn","year":"2020","unstructured":"Krenn, K., H\u00f6bart, P., Poglitsch, M., Croiz\u00e9, A. & Ullrich, R. Equilibrium angiotensin metabolite profiling in patients with acute respiratory distress syndrome indicates angiotensin-converting enzyme Inhibition. Am. J. Respir Crit. Care Med. 202, 1468\u20131471. https:\/\/doi.org\/10.1164\/rccm.201912-2504LE (2020).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"96161_CR36","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1080\/00365513.2021.1926536","volume":"81","author":"BM Henry","year":"2021","unstructured":"Henry, B. M. et al. Serum ACE activity and plasma ACE concentration in patients with SARS-CoV-2 infection. Scand. J. Clin. Lab. Invest. 81, 272\u2013275. https:\/\/doi.org\/10.1080\/00365513.2021.1926536 (2021).","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"96161_CR37","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41467-019-13883-y","volume":"11","author":"S Kimura","year":"2020","unstructured":"Kimura, S. et al. Osteoprotegerin-dependent M cell self-regulation balances gut infection and immunity. Nat. Commun. 11, 234. https:\/\/doi.org\/10.1038\/s41467-019-13883-y (2020).","journal-title":"Nat. Commun."},{"key":"96161_CR38","doi-asserted-by":"publisher","first-page":"648182","DOI":"10.3389\/fimmu.2021.648182","volume":"12","author":"L Sun","year":"2021","unstructured":"Sun, L. et al. Advances in Understanding the roles of CD244 (SLAMF4) in immune regulation and associated diseases. Front. Immunol. 12, 648182. https:\/\/doi.org\/10.3389\/fimmu.2021.648182 (2021).","journal-title":"Front. Immunol."},{"key":"96161_CR39","doi-asserted-by":"publisher","first-page":"107813","DOI":"10.1016\/j.isci.2023.107813","volume":"26","author":"JA Hackney","year":"2023","unstructured":"Hackney, J. A. et al. A myeloid program associated with COVID-19 severity is decreased by therapeutic Blockade of IL-6 signaling. Science 26, 107813. https:\/\/doi.org\/10.1016\/j.isci.2023.107813 (2023).","journal-title":"Science"},{"key":"96161_CR40","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1126\/science.abc6261","volume":"369","author":"PS Arunachalam","year":"2020","unstructured":"Arunachalam, P. S. et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science 369, 1210\u20131220. https:\/\/doi.org\/10.1126\/science.abc6261 (2020).","journal-title":"Science"},{"key":"96161_CR41","doi-asserted-by":"publisher","first-page":"695242","DOI":"10.3389\/fimmu.2021.695242","volume":"12","author":"F Sabbatino","year":"2021","unstructured":"Sabbatino, F. et al. PD-L1 dysregulation in COVID-19 patients. Front. Immunol. 12, 695242. https:\/\/doi.org\/10.3389\/fimmu.2021.695242 (2021).","journal-title":"Front. Immunol."},{"key":"96161_CR42","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/07853890.2022.2162116","volume":"55","author":"B Fialek","year":"2023","unstructured":"Fialek, B. et al. Systematic review with meta-analysis of mid-regional pro-adrenomedullin (MR-proadm) as a prognostic marker in COVID-19-hospitalized patients. Ann. Med. 55, 379\u2013387. https:\/\/doi.org\/10.1080\/07853890.2022.2162116 (2023).","journal-title":"Ann. Med."},{"key":"96161_CR43","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1182\/blood-2011-11-389585","volume":"119","author":"S Elahi","year":"2012","unstructured":"Elahi, S., Niki, T., Hirashima, M. & Horton, H. Galectin-9 binding to Tim-3 renders activated human CD4\u2009+\u2009T cells less susceptible to HIV-1 infection. Blood 119, 4192\u20134204. https:\/\/doi.org\/10.1182\/blood-2011-11-389585 (2012).","journal-title":"Blood"},{"key":"96161_CR44","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00134-007-0561-y","volume":"33","author":"B Temmesfeld-Wollbr\u00fcck","year":"2007","unstructured":"Temmesfeld-Wollbr\u00fcck, B. et al. Adrenomedullin reduces vascular hyperpermeability and improves survival in rat septic shock. Intensive Care Med. 33, 703\u2013710. https:\/\/doi.org\/10.1007\/s00134-007-0561-y (2007).","journal-title":"Intensive Care Med."},{"key":"96161_CR45","doi-asserted-by":"publisher","first-page":"1352583","DOI":"10.3389\/fimmu.2024.1352583","volume":"15","author":"A Baranova","year":"2024","unstructured":"Baranova, A., Luo, J., Fu, L., Yao, G. & Zhang, F. Evaluating the effects of Circulating inflammatory proteins as drivers and therapeutic targets for severe COVID-19. Front. Immunol. 15, 1352583. https:\/\/doi.org\/10.3389\/fimmu.2024.1352583 (2024).","journal-title":"Front. Immunol."},{"key":"96161_CR46","doi-asserted-by":"publisher","first-page":"e00384","DOI":"10.1128\/mbio.00384-21","volume":"12","author":"N Bozorgmehr","year":"2021","unstructured":"Bozorgmehr, N. et al. Galectin-9, a player in cytokine release syndrome and a surrogate diagnostic biomarker in SARS-CoV-2 infection. mBio 12, e00384\u2013e00321. https:\/\/doi.org\/10.1128\/mbio.00384-21 (2021).","journal-title":"mBio"},{"key":"96161_CR47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","volume":"23","author":"CB Jackson","year":"2022","unstructured":"Jackson, C. B., Farzan, M., Chen, B. & Choe, H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell. Biol. 23, 3\u201320. https:\/\/doi.org\/10.1038\/s41580-021-00418-x (2022).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"96161_CR48","doi-asserted-by":"publisher","first-page":"e0135857","DOI":"10.1371\/journal.pone.0135857","volume":"10","author":"M Jabaudon","year":"2015","unstructured":"Jabaudon, M. et al. Soluble forms and ligands of the receptor for advanced glycation end-products in patients with acute respiratory distress syndrome: an observational prospective study. PLoS One. 10, e0135857. https:\/\/doi.org\/10.1371\/journal.pone.0135857 (2015).","journal-title":"PLoS One"},{"key":"96161_CR49","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1097\/01.Ccm.0000262386.32287.29","volume":"35","author":"H Wittkowski","year":"2007","unstructured":"Wittkowski, H. et al. Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit. Care Med. 35, 1369\u20131375. https:\/\/doi.org\/10.1097\/01.Ccm.0000262386.32287.29 (2007).","journal-title":"Crit. Care Med."},{"key":"96161_CR50","doi-asserted-by":"publisher","first-page":"eabn5168","DOI":"10.1126\/scitranslmed.abn5168","volume":"14","author":"ST Chen","year":"2022","unstructured":"Chen, S. T. et al. A shift in lung macrophage composition is associated with COVID-19 severity and recovery. Sci. Transl Med. 14, eabn5168. https:\/\/doi.org\/10.1126\/scitranslmed.abn5168 (2022).","journal-title":"Sci. Transl Med."},{"key":"96161_CR51","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1165\/rcmb.2021-0358OC","volume":"66","author":"CD Russell","year":"2022","unstructured":"Russell, C. D. et al. Tissue proteomic analysis identifies mechanisms and stages of immunopathology in fatal COVID-19. Am. J. Respir Cell. Mol. Biol. 66, 196\u2013205. https:\/\/doi.org\/10.1165\/rcmb.2021-0358OC (2022).","journal-title":"Am. J. Respir Cell. Mol. Biol."},{"key":"96161_CR52","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1186\/s12879-022-07761-0","volume":"22","author":"I Rica\u00f1o-Ponce","year":"2022","unstructured":"Rica\u00f1o-Ponce, I. et al. Characterization of sepsis inflammatory endotypes using circulatory proteins in patients with severe infection: A prospective cohort study. BMC Infect. Dis. 22, 778. https:\/\/doi.org\/10.1186\/s12879-022-07761-0 (2022).","journal-title":"BMC Infect. Dis."},{"key":"96161_CR53","doi-asserted-by":"publisher","first-page":"239732","DOI":"10.3389\/fimmu.2023.1239732","volume":"14","author":"CL Wolf","year":"2023","unstructured":"Wolf, C. L., Pruett, C., Lighter, D. & Jorcyk, C. L. The clinical relevance of OSM in inflammatory diseases: A comprehensive review. Front. Immunol. 14, 239732. https:\/\/doi.org\/10.3389\/fimmu.2023.1239732 (2023).","journal-title":"Front. Immunol."},{"key":"96161_CR54","doi-asserted-by":"publisher","first-page":"702507","DOI":"10.3389\/fcvm.2021.702507","volume":"8","author":"R Moll-Bernardes","year":"2021","unstructured":"Moll-Bernardes, R. et al. IL-10 and IL-12 (p70) levels predict the risk of COVID-19 progression in hypertensive patients: insights from the BRACE-CORONA trial. Front. Cardiovasc. Med. 8, 702507. https:\/\/doi.org\/10.3389\/fcvm.2021.702507 (2021).","journal-title":"Front. Cardiovasc. Med."},{"key":"96161_CR55","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri1001","volume":"3","author":"G Trinchieri","year":"2003","unstructured":"Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133\u2013146. https:\/\/doi.org\/10.1038\/nri1001 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"96161_CR56","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","volume":"9","author":"AM Abel","year":"2018","unstructured":"Abel, A. M., Yang, C., Thakar, M. S. & Malarkannan, S. Natural killer cells: development, maturation, and clinical utilization. Front. Immunol. 9, 1869. https:\/\/doi.org\/10.3389\/fimmu.2018.01869 (2018).","journal-title":"Front. Immunol."},{"key":"96161_CR57","doi-asserted-by":"publisher","first-page":"580237","DOI":"10.3389\/fimmu.2020.580237","volume":"11","author":"M Li","year":"2020","unstructured":"Li, M. et al. Elevated exhaustion levels of NK and CD8\u2009+\u2009T cells as indicators for progression and prognosis of COVID-19 disease. Front. Immunol. 11, 580237. https:\/\/doi.org\/10.3389\/fimmu.2020.580237 (2020).","journal-title":"Front. Immunol."},{"key":"96161_CR58","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1164\/rccm.202106-1514OC","volume":"205","author":"DE Leisman","year":"2022","unstructured":"Leisman, D. E. et al. Alveolar, endothelial, and organ injury marker dynamics in severe COVID-19. Am. J. Respir Crit. Care Med. 205, 507\u2013519. https:\/\/doi.org\/10.1164\/rccm.202106-1514OC (2022).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"96161_CR59","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines (National Institutes of Health, 2021). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK570371\/pdf\/Bookshelf_NBK570371.pdf"},{"key":"96161_CR60","unstructured":"Center for Biologics Evaluation and Research & Center for Drug Evaluation and Research. COVID-19: Developing Drugs and Biological Products for Treatment or prevention - guidance for Industry (U.S. Food and Drug Administration, 2020)."},{"key":"96161_CR61","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of COVID-19 \u2014 final report. N Engl. J. Med. 383, 1813\u20131826. https:\/\/doi.org\/10.1056\/NEJMoa2007764 (2020).","journal-title":"N Engl. J. Med."},{"key":"96161_CR62","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1161\/HYPERTENSIONAHA.119.12786","volume":"74","author":"C Binder","year":"2019","unstructured":"Binder, C. et al. Angs (angiotensins) of the alternative renin-angiotensin system predict outcome in patients with heart failure and preserved ejection fraction. Hypertension 74, 285\u2013294. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.12786 (2019).","journal-title":"Hypertension"},{"key":"96161_CR63","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMc2104192","volume":"384","author":"T Moyo-Gwete","year":"2021","unstructured":"Moyo-Gwete, T. et al. Cross-reactive neutralizing antibody responses elicited by SARS-CoV-2 501Y.V2 (B.1.351). N Engl. J. Med. 384, 2161\u20132163. https:\/\/doi.org\/10.1056\/NEJMc2104192 (2021).","journal-title":"N Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96161-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96161-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96161-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T10:49:01Z","timestamp":1744627741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96161-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["96161"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-96161-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"11 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12799"}}